Show simple item record

dc.contributor.authorSaip, P.
dc.contributor.authorIcli, F.
dc.contributor.authorAltundag, K.
dc.contributor.authorCoskun, U.
dc.contributor.authorPaydas, S.
dc.contributor.authorBasaran, G.
dc.contributor.authorDogu, G. G.
dc.contributor.authorEralp, Y.
dc.contributor.authorUslu, R.
dc.contributor.authorSevinc, A.
dc.contributor.authorOnur, H.
dc.contributor.authorMandel, N. M.
dc.contributor.authorSezgin, C.
dc.contributor.authorAltinbas, M.
dc.contributor.authorGuler, N.
dc.contributor.authorIsikdogan, A.
dc.contributor.authorGokmen, E.
dc.contributor.authorUygun, K.
dc.contributor.authorUstuner, Z.
dc.contributor.authorYaren, A.
dc.date.accessioned2021-03-06T12:05:41Z
dc.date.available2021-03-06T12:05:41Z
dc.date.issued2011
dc.identifier.citationIcli F., Altundag K., Coskun U., Paydas S., Basaran G., Saip P., Dogu G. G. , Eralp Y., Uslu R., Sevinc A., et al., "Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group.", JOURNAL OF CLINICAL ONCOLOGY, cilt.29, 2011
dc.identifier.issn0732-183X
dc.identifier.othervv_1032021
dc.identifier.otherav_f23ad3b5-fdc6-4f62-b02b-55b2a56f47a1
dc.identifier.urihttp://hdl.handle.net/20.500.12627/158890
dc.identifier.urihttps://doi.org/10.1200/jco.2011.29.15_suppl.629
dc.language.isoeng
dc.subjectTıp
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.titleNine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group.
dc.typeMakale
dc.relation.journalJOURNAL OF CLINICAL ONCOLOGY
dc.contributor.department, ,
dc.identifier.volume29
dc.identifier.issue15
dc.contributor.firstauthorID200502


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record